Evidence map›Paper›PMID 32618267›Full record

Trial reportThe American journal of tropical medicine and hygiene2020

Adherence to Mass Drug Administration with Dihydroartemisinin-Piperaquine and

Timothy P Finn, Travis R Porter, Hawela Moonga, Kafula Silumbe, Rachel F Daniels, Sarah K Volkman, Joshua O Yukich, Joseph Keating, Adam Bennett, Richard W Steketee and 2 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of tropical medicine and hygiene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02329301 (Assessing the Effectiveness of Mass Drug Administration), which is not on this map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02329301 nacompletednot on this map

Assessing the Effectiveness of Mass Drug Administration (MDA) With Dihydroartemisinin + Piperaquine for Reducing Malaria Parasite Infection Prevalence and Incidence in Southern Province Zambia

TypeinterventionalSponsorPATHRan2014 to 2020Enrolled2,430ConditionsMalaria, Malaria, FalciparumArmsMDA with DHAp (Eurartesim), Focal MDA with DHAp (Eurartesim)
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Knowledge about Asymptomatic Malaria and Acceptability of UsingInternational journal of environmental research and public health · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Timothy P Finn1Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Travis R Porter1Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Hawela Moonga2National Malaria Elimination Centre, Zambia Ministry of Health, Chainama Hospital Grounds, Lusaka, Zambia.
Kafula Silumbe3PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Rachel F Daniels4Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Sarah K Volkman4Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Joshua O Yukich1Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Joseph Keating1Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Adam Bennett7Malaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California.
Richard W Steketee8PATH MACEPA, Seattle, Washington.
John M Miller3PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Thomas P Eisele1Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Tulane University · USNational HIV/AIDS/STI/TB Council · ZMBroad Institute · USHarvard University · USMinistry of Health · ZMProgram for Appropriate Technology in Health · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mass drug administration (MDA) with artemisinin combination therapy is a potentially useful tool for malaria elimination programs, but its success depends partly on drug effectiveness and treatment coverage in the targeted population. As part of a cluster-randomized controlled trial in Southern Province, Zambia evaluating the impact of MDA and household focal MDA (fMDA) with dihydroartemisinin-piperaquine (DHAp), sub-studies were conducted investigating population drug adherence rates and effectiveness of DHAp as administered in clearing

Indexed as

Drug MonitoringMass Drug AdministrationMedication AdherencePatient Acceptance of Health CarePlasmodium falciparumAdolescentAntimalarialsArtemisininsChildChild, PreschoolDisease EradicationDrug Therapy, CombinationFamily CharacteristicsFemaleHumansInterviews as TopicAntimalarialsArtemisininsartenimolpiperaquinePiperazinesQuinolines

Identifiers

PMID32618267
PMCPMC7416972
OpenAlexW3040066109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.